



Press release |

IBA IMPROVES PATIENT AND STAFF EXPERIENCE AT FRANCIS H. BURR PROTON THERAPY CENTER AT MASSACHUSETTS GENERAL HOSPITAL

IBA COMPLETES FIRST UPGRADE OF TREATMENT ROOM WITH GANTRY ROLLING FLOOR WITHOUT DISRUPTING PATIENT TREATMENTS.

Boston, March 22nd, 2013 — IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce that it completed the first upgrade installation of a Gantry Rolling Floor¹ system at the Francis H. Burr Proton Therapy Center, Massachusetts General Hospital (MGH) in Boston, MA, USA.

This upgrade greatly improves the clinical experience for both the patient and the staff. It provides more flexibility in accessing and interacting with patients during the treatment sessions and this translates into higher efficiency and safety. Furthermore, it provides a soothing treatment environment to patients as well as the clinical staff.

IBA has once again demonstrated its leadership in managing proton therapy installation projects in clinical environments. Careful planning and close collaboration with MGH's staff lead to this successful installation that was delivered by IBA on-time and importantly, without disrupting the ongoing daily treatments for patients.

"The completion of this complex upgrade project demonstrates IBA's commitment and capability to support its customers all over the world in staying at the leading edge of cancer treatment. It is a significant step forward in enabling proton therapy professionals to work in an ever more ergonomic, safe and efficient treatment environment," said Olivier Legrain, Chief Executive Officer of IBA. He added, *"Proton Therapy professionals and their patients will be able to experience a soothing state-of-the-art treatment environment."*

"Treatment ergonomics and patient safety are a priority for proton therapy and a gantry floor can help achieve this effectively. The organization and coordination between the MGH and IBA has shown how well these two parties are able to work together and perform the installation without disrupting patient treatment which is a great achievement," said Torunn Yock, MD at the Francis H. Burr Proton Therapy Center, Massachusetts General Hospital (MGH) in Boston

¹ Gantry Rolling Floor system consists of a caterpillar based rotating floor system within the gantry structure that enables the physician to have access to the patient lying on the treatment table.

Press release |

The second treatment gantry room will be upgraded with a Gantry Rolling Floor system later in 2013.

Treatment room before



Treatment room after



About Proton Therapy

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world's clinically based proton therapy facilities. To date they include 13 operational proton therapy centers worldwide, and 12 more centers in development.

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets.

The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.



Press release |

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact

Olivier de Sadeleer

IBA

Marketing Manager

Phone : +32 10 203 342

E-mail. Olivier.deSadeleer@iba-group.com

Thomas Ralet

IBA

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire
Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com